Sugi Predict

Sugi Predict / Compounds / SCHEMBL17064635

SCHEMBL17064635

SCHEMBL17064635

NC(=O)c1cccc(C(O)c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.54
▸ PARP1 P09874 7/20 0.54
▸ MAPT P10636 3/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ RECQL P46063 2/20 0.54
▸ PMP22 Q01453 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ CHEK2 O96017 2/20 0.50
▸ LMNA P02545 2/20 0.46
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17064845 0.92 CA1 (0.60) CTSLPARP1MAPTCYP3A4RECQL
SCHEMBL17064839 0.85 CHEK2 (0.56) CTSLPARP1MAPTCYP3A4RECQL
SCHEMBL3346923 0.85 CA1 (0.63) CTSLMAPTCYP3A4RECQLPMP22
SCHEMBL15264145 0.83 MAPT (0.64) MAPTCYP3A4RECQLPMP22HSD17B10
SCHEMBL6283656 0.83 PARP1 (0.47) CTSLPARP1MAPTCYP3A4RECQL
SCHEMBL3020894 0.82 POLB (0.60) PARP1MAPTCYP3A4RECQLPMP22
SCHEMBL27613443 0.82 PARP1 (0.55) PARP1MAPTCYP3A4RECQLPMP22
SCHEMBL17064514 0.82 PARP1 (0.43) CTSLPARP1MAPTCYP3A4RECQL
SCHEMBL10676975 0.81 KMT2A (0.50) CTSLMAPTCYP3A4RECQLPMP22
SCHEMBL17064476 0.80 PARP1 (0.49) CTSLPARP1MAPTCYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708332-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11685721-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-06-27 — — US disclosed
EP-4180424-A1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2023-05-17 — — EP disclosed
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-02-23 — — US disclosed
US-10633345-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2020-04-28 — — US disclosed
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2019-10-24 — — US disclosed
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-12-13 — — US disclosed
US-10125102-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2018-11-13 — — US disclosed
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-09-13 — — US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 — — US disclosed
EP-3113772-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2017-01-11 — — EP disclosed
CN-106257976-A Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2016-12-28 — — CN disclosed
WO-2015134998-A1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2015-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CTSL 132/4885PARP1 1785/4885MAPT 3007/4885
US-20180354906-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CTSL 129/4885PARP1 1728/4885MAPT 2984/4885
US-11708332-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 CTSL 132/4885PARP1 1785/4885MAPT 3007/4885
US-10329260-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-10125102-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-20190322626-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CTSL 101/4885PARP1 1888/4885MAPT 2685/4885
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CTSL 129/4885PARP1 1728/4885MAPT 2984/4885
US-10633345-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CTSL 129/4885PARP1 1728/4885MAPT 2984/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 CTSL 101/4885PARP1 1888/4885MAPT 2685/4885
US-20180258049-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 CTSL 109/4885PARP1 1940/4885MAPT 2830/4885
US-11685721-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 CTSL 129/4885PARP1 1728/4885MAPT 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.